Upsher-Smith Champions Duchenne Muscular Dystrophy Support
Upsher-Smith's Commitment to Rare Disease Community
Visit Upsher-Smith at the upcoming Parent Project Muscular Dystrophy (PPMD) Annual Conference, where they will highlight support services and resources related to Deflazacort Tablets. This commitment underscores their dedication to patients and families facing rare diseases.
Engagement at PPMD Annual Conference
During this year's PPMD Annual Conference, representatives from Upsher-Smith will engage with attendees, sharing vital information about Deflazacort Tablets. This participation symbolizes Upsher-Smith’s dedication to the Duchenne muscular dystrophy (DMD) community, offering insights into their best-in-class support services tailored for patients.
Providing Valuable Resources
Founded in 1919, Upsher-Smith has over a century of experience serving patients' unique needs, particularly in the realm of rare diseases. Jim Maahs, Head of Commercial, emphasized, "Experience matters in rare disease." His invitation to conference attendees reflects Upsher-Smith's unwavering commitment to elevate support standards for families impacted by DMD.
Deflazacort Tablets Overview
Upsher-Smith’s Deflazacort Tablets, an AB-rated generic version of Emflaza, are specially designed for the treatment of DMD in patients aged five and above. Available in various strengths, these tablets ensure that patients receive comparable efficacy and safety as the named brand treatments.
Indications and Safety Information
Deflazacort Tablets are recognized for treating DMD across a range of patient ages. However, important safety considerations must be taken into account. It is essential to monitor patients for potential adverse effects and be aware of contraindications that could complicate treatment.
Contraindications and Warnings
Patients with known hypersensitivity to deflazacort or any inactive ingredients should avoid this medication. Additionally, the use of corticosteroids like Deflazacort can result in significant endocrine function changes, which can be particularly serious with long-term use. Patients must be carefully monitored for conditions such as Cushing's syndrome and hyperglycemia.
Addressing Behavioral and Mood Changes
During treatment, patients may experience various behavioral and mood disturbances, which can differ in severity. Educating both patients and caregivers on these potential changes is crucial to ensuring comprehensive care and support.
Encouraging Ongoing Communication
Healthcare providers are encouraged to maintain open communication with their patients and families, taking particular notice of any ongoing infections, vaccinations, or significant changes in the patient's condition during treatment with Deflazacort.
Contact and Support Resources
Upsher-Smith Laboratories continues to commit to patient safety and well-being. For further information or to report any adverse reactions, patients or caregivers can reach Upsher-Smith directly or visit their website for comprehensive resources on Deflazacort Tablets.
About Upsher-Smith and Bora Group
Upsher-Smith Laboratories, now a member of Bora Group, is dedicated to providing high-quality pharmaceutical products. With a history steeped in patient care, Upsher-Smith’s mission aligns with the goals of the Bora Group to enhance pharmaceutical manufacturing and availability worldwide.
Frequently Asked Questions
What is Upsher-Smith's role at the PPMD annual conference?
Upsher-Smith will showcase its commitment to DMD by providing resources and support services related to Deflazacort Tablets during the PPMD conference.
Who can use Deflazacort Tablets?
Deflazacort Tablets are indicated for the treatment of Duchenne muscular dystrophy in patients aged five years and older.
What are the common side effects of Deflazacort?
Some common side effects include weight gain, increased appetite, and mood swings. Patients should be monitored closely for these reactions.
How can patients report adverse reactions?
Patients can report any adverse reactions to Upsher-Smith at their dedicated hotline or through the FDA’s MedWatch program.
What is the history of Upsher-Smith?
Founded in 1919, Upsher-Smith has a long-standing tradition of supporting patients, especially in the rare disease community.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
